Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 11.38
ALXN's Cash to Debt is ranked higher than
70% of the 1256 Companies
in the Global Biotechnology industry.

( Industry Median: 47.96 vs. ALXN: 11.38 )
ALXN' s 10-Year Cash to Debt Range
Min: 0.49   Max: No Debt
Current: 11.38

Equity to Asset 0.80
ALXN's Equity to Asset is ranked higher than
82% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. ALXN: 0.80 )
ALXN' s 10-Year Equity to Asset Range
Min: 0.04   Max: 0.95
Current: 0.8

0.04
0.95
Interest Coverage 128.41
ALXN's Interest Coverage is ranked higher than
56% of the 563 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ALXN: 128.41 )
ALXN' s 10-Year Interest Coverage Range
Min: 14.38   Max: 9999.99
Current: 128.41

14.38
9999.99
F-Score: 8
Z-Score: 30.72
M-Score: -2.43
WACC vs ROIC
12.66%
37.74%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 38.68
ALXN's Operating margin (%) is ranked higher than
97% of the 1033 Companies
in the Global Biotechnology industry.

( Industry Median: -76.30 vs. ALXN: 38.68 )
ALXN' s 10-Year Operating margin (%) Range
Min: -10370.21   Max: 35.65
Current: 38.68

-10370.21
35.65
Net-margin (%) 23.34
ALXN's Net-margin (%) is ranked higher than
94% of the 1033 Companies
in the Global Biotechnology industry.

( Industry Median: -78.15 vs. ALXN: 23.34 )
ALXN' s 10-Year Net-margin (%) Range
Min: -10220.86   Max: 76.31
Current: 23.34

-10220.86
76.31
ROE (%) 18.02
ALXN's ROE (%) is ranked higher than
95% of the 1151 Companies
in the Global Biotechnology industry.

( Industry Median: -34.30 vs. ALXN: 18.02 )
ALXN' s 10-Year ROE (%) Range
Min: -136.75   Max: 63.11
Current: 18.02

-136.75
63.11
ROA (%) 14.09
ALXN's ROA (%) is ranked higher than
95% of the 1260 Companies
in the Global Biotechnology industry.

( Industry Median: -26.94 vs. ALXN: 14.09 )
ALXN' s 10-Year ROA (%) Range
Min: -45.22   Max: 46.71
Current: 14.09

-45.22
46.71
ROC (Joel Greenblatt) (%) 151.92
ALXN's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 1234 Companies
in the Global Biotechnology industry.

( Industry Median: -394.00 vs. ALXN: 151.92 )
ALXN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -963.15   Max: 151.22
Current: 151.92

-963.15
151.22
Revenue Growth (3Y)(%) 38.70
ALXN's Revenue Growth (3Y)(%) is ranked higher than
95% of the 699 Companies
in the Global Biotechnology industry.

( Industry Median: -1.10 vs. ALXN: 38.70 )
ALXN' s 10-Year Revenue Growth (3Y)(%) Range
Min: -70.5   Max: 498.1
Current: 38.7

-70.5
498.1
EBITDA Growth (3Y)(%) 46.50
ALXN's EBITDA Growth (3Y)(%) is ranked higher than
97% of the 699 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. ALXN: 46.50 )
ALXN' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -10.1   Max: 72.8
Current: 46.5

-10.1
72.8
EPS Growth (3Y)(%) 34.70
ALXN's EPS Growth (3Y)(%) is ranked higher than
94% of the 721 Companies
in the Global Biotechnology industry.

( Industry Median: -6.70 vs. ALXN: 34.70 )
ALXN' s 10-Year EPS Growth (3Y)(%) Range
Min: -15.3   Max: 77.3
Current: 34.7

-15.3
77.3
» ALXN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

ALXN Guru Trades in Q4 2013

Eric Mindich Sold Out
Frank Sands 7,370,601 sh (-2.25%)
Andreas Halvorsen 2,877,008 sh (-16.72%)
Pioneer Investments 30,500 sh (-64.11%)
Steven Cohen 67,536 sh (-66.45%)
» More
Q1 2014

ALXN Guru Trades in Q1 2014

Paul Tudor Jones 5,725 sh (New)
Ray Dalio 50,371 sh (New)
Joel Greenblatt 5,026 sh (New)
John Burbank 1,318 sh (New)
Ron Baron 10,218 sh (New)
Pioneer Investments 31,453 sh (+3.12%)
Frank Sands 5,268,418 sh (-28.52%)
Steven Cohen 45,697 sh (-32.34%)
Andreas Halvorsen 1,836,658 sh (-36.16%)
» More
Q2 2014

ALXN Guru Trades in Q2 2014

Jim Simons 245,552 sh (New)
Joel Greenblatt 17,094 sh (+240.11%)
Andreas Halvorsen 2,006,092 sh (+9.23%)
Pioneer Investments 31,934 sh (+1.53%)
Frank Sands 5,279,782 sh (+0.22%)
Steven Cohen 11,700 sh (unchged)
John Burbank Sold Out
Ron Baron 10,145 sh (-0.71%)
Ray Dalio 26,332 sh (-47.72%)
Paul Tudor Jones 1,326 sh (-76.84%)
» More
Q3 2014

ALXN Guru Trades in Q3 2014

Paul Tudor Jones 3,120 sh (+135.29%)
Ron Baron 12,941 sh (+27.56%)
Andreas Halvorsen 2,198,451 sh (+9.59%)
Frank Sands 5,311,488 sh (+0.6%)
Ray Dalio Sold Out
Steven Cohen Sold Out
Pioneer Investments 30,500 sh (-4.49%)
Jim Simons 206,152 sh (-16.05%)
Joel Greenblatt 1,804 sh (-89.45%)
» More
» Details

Insider Trades

Latest Guru Trades with ALXN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Andreas Halvorsen 2014-09-30 Add 9.59%0.13%$155.06 - $173.08 $ 188.0514%2198451
Ray Dalio 2014-09-30 Sold Out 0.03%$155.06 - $173.08 $ 188.0514%0
Joel Greenblatt 2014-09-30 Reduce -89.45%0.03%$155.06 - $173.08 $ 188.0514%1804
Ron Baron 2014-09-30 Add 27.56%$155.06 - $173.08 $ 188.0514%12941
Andreas Halvorsen 2014-06-30 Add 9.23%0.12%$139.61 - $170.2 $ 188.0519%2006092
Ray Dalio 2014-06-30 Reduce -47.72%0.03%$139.61 - $170.2 $ 188.0519%26332
Joel Greenblatt 2014-06-30 Add 240.11%0.02%$139.61 - $170.2 $ 188.0519%17094
John Burbank 2014-06-30 Sold Out 0.01%$139.61 - $170.2 $ 188.0519%0
Frank Sands 2014-03-31 Reduce -28.52%0.74%$129.82 - $183.89 $ 188.0519%5268418
Andreas Halvorsen 2014-03-31 Reduce -36.16%0.65%$129.82 - $183.89 $ 188.0519%1836658
Ray Dalio 2014-03-31 New Buy0.06%$129.82 - $183.89 $ 188.0519%50371
Joel Greenblatt 2014-03-31 New Buy0.01%$129.82 - $183.89 $ 188.0519%5026
Ron Baron 2014-03-31 New Buy0.01%$129.82 - $183.89 $ 188.0519%10218
John Burbank 2014-03-31 New Buy0.01%$129.82 - $183.89 $ 188.0519%1318
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Alexion Pharmaceuticals Inc

Weekly CFO Sells Highlight: Alexion Pharmaceuticals Inc, Equity Residential, Tableau Software Inc.
According to GuruFocus Insider Data, the recent CFO sales were: Alexion Pharmaceuticals Inc, Equity Residential, and Tableau Software Inc. Read more...
Weekly Insider Sells Highlight: ORCL, ALXN, WAT, XRAY
According to GuruFocus Insider Data, the largest insider sells during the past week were: Oracle Corporation (ORCL), Alexion Pharmaceuticals Inc (ALXN), Waters Corp (WAT) and DENTSPLY International Inc (XRAY). Read more...
Alexion CEO Receives Nearly $17 Million for Sale of Company Stock
The CEO of Alexion Pharmaceuticals Inc (ALXN), Leonard Bell, sold more than 100,000 shares of company stock Wednesday for nearly $17 million. At a price of $160.71 per share, the sale of 105,000 shares of company stock brought $16,874,551. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 77.50
ALXN's P/E(ttm) is ranked higher than
90% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ALXN: 77.50 )
ALXN' s 10-Year P/E(ttm) Range
Min: 13.92   Max: 1113.68
Current: 77.5

13.92
1113.68
Forward P/E 24.94
ALXN's Forward P/E is ranked higher than
93% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ALXN: 24.94 )
N/A
PE(NRI) 76.80
ALXN's PE(NRI) is ranked higher than
90% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ALXN: 76.80 )
ALXN' s 10-Year PE(NRI) Range
Min: 13.96   Max: 1058
Current: 76.8

13.96
1058
P/B 11.90
ALXN's P/B is ranked higher than
64% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 6.38 vs. ALXN: 11.90 )
ALXN' s 10-Year P/B Range
Min: 1.73   Max: 162.14
Current: 11.9

1.73
162.14
P/S 18.20
ALXN's P/S is ranked higher than
77% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 28.95 vs. ALXN: 18.20 )
ALXN' s 10-Year P/S Range
Min: 9.66   Max: 1115.3
Current: 18.2

9.66
1115.3
PFCF 79.30
ALXN's PFCF is ranked higher than
93% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ALXN: 79.30 )
ALXN' s 10-Year PFCF Range
Min: 40   Max: 99999999.99
Current: 79.3

40
99999999.99
POCF 65.58
ALXN's POCF is ranked higher than
90% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ALXN: 65.58 )
ALXN' s 10-Year POCF Range
Min: 33.16   Max: 83.87
Current: 65.58

33.16
83.87
EV-to-EBIT 43.47
ALXN's EV-to-EBIT is ranked higher than
92% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ALXN: 43.47 )
ALXN' s 10-Year EV-to-EBIT Range
Min: -98.6   Max: 893.9
Current: 43.47

-98.6
893.9
PEG 1.47
ALXN's PEG is ranked higher than
99% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ALXN: 1.47 )
ALXN' s 10-Year PEG Range
Min: 0.68   Max: 2.63
Current: 1.47

0.68
2.63
Shiller P/E 132.50
ALXN's Shiller P/E is ranked higher than
94% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ALXN: 132.50 )
ALXN' s 10-Year Shiller P/E Range
Min: 98.32   Max: 655.33
Current: 132.5

98.32
655.33
Current Ratio 5.09
ALXN's Current Ratio is ranked higher than
74% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: 4.74 vs. ALXN: 5.09 )
ALXN' s 10-Year Current Ratio Range
Min: 1.38   Max: 52.92
Current: 5.09

1.38
52.92
Quick Ratio 4.82
ALXN's Quick Ratio is ranked higher than
75% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. ALXN: 4.82 )
ALXN' s 10-Year Quick Ratio Range
Min: 1.38   Max: 52.92
Current: 4.82

1.38
52.92
Days Inventory 256.72
ALXN's Days Inventory is ranked higher than
80% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ALXN: 256.72 )
ALXN' s 10-Year Days Inventory Range
Min: 202.61   Max: 959.95
Current: 256.72

202.61
959.95
Days Sales Outstanding 76.73
ALXN's Days Sales Outstanding is ranked higher than
79% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 115.94 vs. ALXN: 76.73 )
ALXN' s 10-Year Days Sales Outstanding Range
Min: 95.13   Max: 451.45
Current: 76.73

95.13
451.45

Valuation & Return

vs
industry
vs
history
Price/Net Cash 36.80
ALXN's Price/Net Cash is ranked higher than
75% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 55.00 vs. ALXN: 36.80 )
ALXN' s 10-Year Price/Net Cash Range
Min: 1.37   Max: 205.55
Current: 36.8

1.37
205.55
Price/Net Current Asset Value 26.40
ALXN's Price/Net Current Asset Value is ranked higher than
75% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 31.07 vs. ALXN: 26.40 )
ALXN' s 10-Year Price/Net Current Asset Value Range
Min: 1.37   Max: 470.75
Current: 26.4

1.37
470.75
Price/Tangible Book 16.40
ALXN's Price/Tangible Book is ranked higher than
67% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 9.50 vs. ALXN: 16.40 )
ALXN' s 10-Year Price/Tangible Book Range
Min: 1.15   Max: 82.09
Current: 16.4

1.15
82.09
Price/DCF (Projected) 5.90
ALXN's Price/DCF (Projected) is ranked higher than
94% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ALXN: 5.90 )
ALXN' s 10-Year Price/DCF (Projected) Range
Min: 4.34   Max: 142.19
Current: 5.9

4.34
142.19
Price/Median PS Value 1.00
ALXN's Price/Median PS Value is ranked higher than
86% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 2.32 vs. ALXN: 1.00 )
ALXN' s 10-Year Price/Median PS Value Range
Min: 0.35   Max: 56.1
Current: 1

0.35
56.1
Price/Peter Lynch Fair Value 3.10
ALXN's Price/Peter Lynch Fair Value is ranked higher than
98% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ALXN: 3.10 )
ALXN' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.56   Max: 4.22
Current: 3.1

0.56
4.22
Price/Graham Number 7.50
ALXN's Price/Graham Number is ranked higher than
90% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ALXN: 7.50 )
ALXN' s 10-Year Price/Graham Number Range
Min: 2.04   Max: 22.85
Current: 7.5

2.04
22.85
Earnings Yield (Greenblatt) 2.30
ALXN's Earnings Yield (Greenblatt) is ranked higher than
91% of the 1236 Companies
in the Global Biotechnology industry.

( Industry Median: -5.70 vs. ALXN: 2.30 )
ALXN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 3
Current: 2.3

0.1
3
Forward Rate of Return (Yacktman) 53.52
ALXN's Forward Rate of Return (Yacktman) is ranked higher than
96% of the 163 Companies
in the Global Biotechnology industry.

( Industry Median: 14.57 vs. ALXN: 53.52 )
ALXN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -18.5   Max: 75.6
Current: 53.52

-18.5
75.6

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:AXP.Germany, 0QZM.UK,
Alexion Pharmaceuticals Inc is a Delaware based company, incorporated in 1992. The Company is a biopharmaceutical company serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its marketed product Soliris (eculizumab) is the first and only therapeutic approved for patients with two ultra-rare and severe disorders resulting from chronic uncontrolled activation of the complement component of the immune system: paroxysmal nocturnal hemoglobinuria, an ultra-rare and life-threatening blood disorder, and atypical hemolytic uremic syndrome, an ultra-rare and life-threatening genetic disease. The Company is also evaluating other potential indications for Soliris in other diseases in which chronic uncontrolled complement activation is the underlying mechanism. Soliris is designed to inhibit a specific aspect of the complement component of the immune system and thereby treat inflammation associated with chronic disorders in the therapeutic areas of hematology, nephrology, transplant rejection, neurology and ophthalmology. The Company competes with large pharmaceutical companies that produce and market synthetic compounds and with specialized biotechnology firms in the United States, Europe and elsewhere, as well as a growing number of large pharmaceutical companies that are applying biotechnology to their operations.
» More Articles for ALXN

Headlines

Articles On GuruFocus.com
Alexion Pharma Downgraded Despite Progress in Pipeline Jan 05 2015 
Weekly CFO Sells Highlight: Alexion Pharmaceuticals Inc, Equity Residential, Tableau Software Inc. Dec 08 2014 
Weekly Insider Sells Highlight: ORCL, ALXN, WAT, XRAY Dec 08 2014 
CEO of Alexion Pharmaceuticals Sells Company Stock Sep 29 2014 
Alexion CEO Receives Nearly $17 Million for Sale of Company Stock Aug 14 2014 
Weekly CFO Sells Highlight: Facebook Inc., Cardinal Health Inc., Alexion Pharmaceuticals Inc., Therm Feb 10 2014 
Weekly Insider Sells Highlight: EA, ALXN, AAL, TMO Feb 09 2014 
You Can No Longer Ignore Biotech Feb 07 2014 
Six High-Impact Sells - Viking Global Investors Aug 26 2013 
CEO of Alexion Pharmaceuticals Inc. Leonard Bell Sold 140,000 Shares Aug 19 2013 

More From Our Partners
Zacks Rank #1 Additions for Thursday - Tale of the Tape Jan 29 2015 - ZACKS

More From Other Websites
Biogen, Alexion Earnings Top Views, Shares Jump Jan 29 2015
Alexion Pharmaceuticals Names COO to CEO Jan 29 2015
ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Jan 29 2015
Thursday's Market Recap Jan 29 2015
Incyte's Phase III RESPONSE Data on Jakafi Published - Analyst Blog Jan 29 2015
Stocks Finish Strong; Facebook, Alexion Reverse Higher Jan 29 2015
Alexion Misses on Q4 Earnings, 2015 Outlook Disappoints - Analyst Blog Jan 29 2015
Salix Financial Results Need Correcting: Audit Committee - Analyst Blog Jan 29 2015
Baird Says Alexion Pharmaceuticals Guidance Is Conservative Jan 29 2015
Alexion Pharmaceuticals: When Tax Rate Trumps FX Jan 29 2015
Alexion Beats Q4 Estimates, Appoints New CEO Jan 29 2015
Celgene Q4 Earnings & Revenues In Line, Revlimid Sales Up - Analyst Blog Jan 29 2015
Vertex Posts Wider 4Q Loss, Affirms Kalydeco Outlook - Analyst Blog Jan 29 2015
Alexion Pharmaceuticals Inc Earnings Call scheduled for 10:00 am ET today Jan 29 2015
Zacks Rank #1 Additions for Thursday - Tale of the Tape Jan 29 2015
Pluristem Therapeutics (PSTI) in Focus: Stock Surges 20.4% - Tale of the Tape Jan 29 2015
Alexion (ALXN) Misses on Q4 Earnings, Appoints New CEO - Tale of the Tape Jan 29 2015
Q4 2014 Alexion Pharmaceuticals Inc Earnings Release - Before Market Open Jan 29 2015
Alexion beats Street 4Q forecasts Jan 29 2015
Alexion beats Street 4Q forecasts Jan 29 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK